Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc.Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to

Related Keywords

Ukraine ,Eli Lilly ,Patrick Crutcher ,Garrya Neil ,Jonathan Goldman ,Chris Brinzey ,Aaron Kantoff ,Schulte Roth Zabel ,Christopher Sullivan ,Samantha Truex ,Patrickj Crutcher ,Goodwin Procter ,Oppenheimer Co ,Almatabio Inc ,Exchange Commission ,Acelyrin Inc ,Nasdaq ,Wyrick Robbins Yates Ponton ,Avalo Therapeutics Inc ,Commodore Capital ,Deep Track Capital ,Wyrick Robbins Yates ,Schulte Roth ,Gunderson Dettmer Stough Villeneuve Franklin ,Private Securities Litigation Reform Act ,Middle East ,